New 5-(pyridin-3-yl)-1,3,4-oxadiazoles derivatives as VEGFR2 inhibitors: in silico study, synthesis, and cytotoxicity evaluation
Research in Pharmaceutical Sciences · 2026-05 · 21 (3) · 278-291
DOI: 10.4103/rps.rps_222_25 ↗Kurz gefasst
Fachartikel in der Zeitschrift Research in Pharmaceutical Sciences, online erschienen am 10.05.2026. Verfasst von Ahmed Nasser Abdulhussein und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Chemistry, College of Pharmacy, University of Baghdad, Baghdad, Iraq. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background and purpose: Angiogenesis, regulated by vascular endothelial growth factor receptor 2 (VEGFR-2), has a key role in tumor progression, especially in common cancers, including colorectal and renal cancer. Inhibiting VEGFR-2 is a promising therapeutic approach. This research aimed to design, synthesize, and biologically evaluate new 5-(pyridine-3-yl)-1,3,4-oxadiazole derivatives as potential VEGFR-2 inhibitors. Experimental approach: A new series of derivatives (AM3-AM6) was synthesized through S-alkylation of 5-(pyridin-3-yl)-1,3,4-oxadiazole-2-thiol and hydrazinolysis reactions, followed by condensation with aldehydes. The compounds were analyzed using FT-IR, 1 H-NMR, and 13 C-NMR spectroscopy. Molecular modelling studies, including docking (PDB ID: 4ASD), ADMET prediction, and molecular dynamics (MD) simulations, were performed to evaluate binding affinity, pharmacokinetic properties, and complex stability. Cytotoxicity was assessed via MTT assay against HT-29 (colorectal), ACHN (renal), and L929 (normal) cell lines. Findings/Results: Docking results revealed strong binding to VEGFR-2, with compound AM3 showing the best docking score (ΔG = -11.613 kcal/mol). MD simulations confirmed the high stability of the AM3-VEGFR-2 complex with consistent RMSD values and persistent interactions with GLU885 and ASP1046. In vitro, AM4 exhibited a significant cytotoxic effect against HT-29 cells (IC 50 = 38.94 μM), compared to sorafenib (IC 50 = 9.73), while all compounds were non-toxic toward L929 cells. Conclusions and implications: In silico and in vitro results demonstrated that the new 5-(pyridine-3-yl)-1,3,4-oxadiazole derivatives possess favorable drug-like properties and selective anti-proliferative activity against colorectal and renal cancer cells. These findings suggest that this scaffold is a valuable starting point for developing novel selective VEGFR-2 inhibitors as anticancer agents.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmaceutical Chemistry, College of Pharmacy, University of Baghdad, Baghdad, Iraq.
Zitieren
APA
Abdulhussein, A. N., & Oleiwi, M. A. (2026). New 5-(pyridin-3-yl)-1,3,4-oxadiazoles derivatives as VEGFR2 inhibitors: in silico study, synthesis, and cytotoxicity evaluation. Research in Pharmaceutical Sciences, 21(3), 278-291. https://doi.org/10.4103/rps.rps_222_25
Vancouver
Abdulhussein AN, Oleiwi MA. New 5-(pyridin-3-yl)-1,3,4-oxadiazoles derivatives as VEGFR2 inhibitors: in silico study, synthesis, and cytotoxicity evaluation. Research in Pharmaceutical Sciences. 2026;21(3):278-291. doi:10.4103/rps.rps_222_25
BibTeX
@article{Abdulhussein2026,
author = {Abdulhussein, Ahmed Nasser and Oleiwi, Mohammed Abdulameer},
title = {New 5-(pyridin-3-yl)-1,3,4-oxadiazoles derivatives as VEGFR2 inhibitors: in silico study, synthesis, and cytotoxicity evaluation},
journal = {Research in Pharmaceutical Sciences},
year = {2026},
volume = {21},
number = {3},
pages = {278--291},
doi = {10.4103/rps.rps_222_25}
}
EUVIMED